Consumption of antibiotics and their possible relationship with bacterial resistance in the "Costa de Ponent" health region: analysis of evolution through the initial and end periods of the last decade
Abstract
Objective: To analyse antibiotic consumption (ABC) and its trend in primary care in an area with a high rate of bacterial resistance during the periods 1993-96 and 2000-02.
Design: Comparative, retrospective analysis.
Setting: Costa de Ponent Health Region. Population in 1993-96 period was 1,158,098 inhabitants; in 2000-02 period, 1,188,007 inhabitants.
Participants: Those patients in the Area who took AB during the periods under study.
Measurements: Data obtained from the appropriate records of the Catalan Health Service. Measurement of ABC was the Defined Daily Dose (DDD)/1000 inhabitants/day (DID) [criteria of the WHO Collaborating Centre for Drugs Statistics Methodology]. Trends were quantified as percentage increase or drop, comparing the 1993-96 and 2000-02 periods. The U Mann-Whitney test was used.
Results: Overall consumption was high, with a light fall from 17.049 DID during the first period to 15.826 DID in the second (-7.1%). Amoxycillin increased from 4.878 DID (57.6%) to 6.19 DID (67.6%) (+26.8%), but amoxycillin-clavulanic did not rise. The percentages of macrolides, quinolones, cephalosporins, sulphonamides, and tetracyclines were higher in the first period. The variations in the consumption of clarithromycin, azithromycin, cefuroxime, cefixime, and ciprofloxacin between the two periods was the most notable point.
Conclusions: Although overall ABC was high and in accord with the high rate of bacterial resistance in our area, a satisfactory evolutionary trend…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
- Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana
- Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains
- Incidence and factors associated with development of phlebitis: results of a pilot study cohort
- Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.